StaGen

Our company StaGen Ltd. specializes in genetics, statistics and data analysis. Initially, our company was established to contribute to individualized medicine and pharmacogenomics from the field of statistical genetics. Currently, however, we also focus on data analysis and statistical analysis of non-genetic data sets in medicine and health care.

The aims of StaGen as a company are to promote world business in the field of medicine and health care and to contribute to the society and the people in medical and biological researches, clinical medicine and health care by use of the knowledge and technology of genetics, statistics and data analysis.

The role of data analysis and statistical analysis will become bigger and bigger in the field of medicine and health care. This is because the targets in this field are not materials but humans. In product-making companies, the workers have to perform fixed operations and make uniform products. In service industries, however, the targets are not products but humans. Unlike products, humans have variations. It is obvious that we cannot cope with all the people by a single uniform operation.

First of all, the genetic information varies between different individuals. Even among a single ethnic group, about 3 million words among 3 billion words are different between different individuals. In addition, gender, age and various environmental factors contribute to the development of diseases and health problems in humans.

As stated above, it is not appropriate to cope with people with large variations using a single uniform method. Undoubtedly, we should obtain the precise information of each individual and treat the individual according to the obtained information. Unfortunately, however, we had not been able to obtain sufficient information, and that was why we had to treat the people by a uniform method.

Owing to the development of computer and bio-research technologies, a huge scale of data are now available. The entire genetic information of a single individual is described with about 3 billion genome information. Of them, 500 thousand important words that are different between individuals are now routinely available. Even more, individual 3 billion words are expected to be obtained at reasonable prices in a few years.

In addition, the development of electronic medical records, electronic journals and internet have contributed to the generation of a huge size of non-genetic data. It is expected that the analysis of such huge-scale data will enable people to use the results of the analysis for the treatment of disease and health care optimized to the individuals.

Drugs are a powerful tool for the maintenance of human health. Drugs have made most of infectious diseases non-death threatening conditions. Drugs have prolonged the lives of cancer patients. Drugs have extremely improved the symptoms of the patients with rheumatic and collagen diseases. However, drugs are not effective to all the patients. They sometimes cause severe adverse events in some patients.

When a drug is effective for a disease, we call that fact as "effectiveness". If the drug does not cause too much adverse events, we call that fact as "safety". Whether a drug is a good one depends on the effectiveness and safety. World pharmaceutical companies are competing with each other for the development of drugs with effectiveness and safety.

If we admit that humans have significant "variations", the only method to examine the effectiveness and safety of a drug is to perform the statistical analysis on the data obtained from the experiments in which the drug is administered to humans. The results from in vitro and animal experiments may be useful; however, it turned out to be too risky to rely on such data.

Therefore, the data analysis and statistical analysis are now considered to be extremely important to develop a new drug or introduce a drug from another country.

It has become apparent that the effectiveness and safety of a drug is different between different individuals with variations in genomic sequences. Because of that reason, many drug labels now have such descriptions as "When this drug is administered to a patient with this genotype, care should be taken" or "The dose of this drug should be reduced to 1/5 when it is administered to a patient with this genetic information".

In addition, the storage or examination of genes from humans has become a routine procedure in new drug development. Many people have reached a conclusion that such genetic tests are inevitable to send really useful drugs that are effective and safe to the patients.

However, a problem is that it is quite difficult to analyze the individual genetic data. This research field is called "statistical genetics" or "pharmacogenomics" that is a mixture of medicine and mathematics. Long extensive learning and experience are necessary to become a master in that field.

Unfortunately, however, there is a shortage of such talents with high technologies and knowledge even in the world. Technologies and talents that are hard to surpass can be the most powerful tool for the industries in developed countries. It is because the technologies and talents that can easily be copied tend to flow out to developing countries.

When the best method is known, the data analysis is not necessary. If the targets are uniform, the data analysis is not so important either. However, the data analysis is always important when we have to cope with uncertainty and variation. This is because, in such cases, perfect prediction of the outcome is impossible before the action. Only after the data analysis and statistical analysis, a prediction of the outcome becomes feasible.

The fields that include such uncertainty and variation are policy making, finance, medicine, drug development,marketing and information technology. The data analysis and statistical analysis have become inevitable for the decision making in those fields. Otherwise, people have to make decisions depending on "taste", "intuition", "feeling" and "interest". However, the latter methods for making decisions are the most inappropriate and the most problematic in the information-oriented society.

StaGen Ltd. has employees with sophisticated data analysis and statistical analysis technologies. In addition, we possess, in our company, the system for the education and self-learning of such technologies.

We focus on the analysis of the data that include genetic information; however, the data without genetic information are also the targets of our business. We StaGen has sufficient experience in the field of data analysis and statistical analysis, and, therefore, can return reliable results of the analysis to the customers.

Site policy | Top